DP
CLDX icon

DSAM Partners’s Celldex Therapeutics CLDX Stock Holding History

DSAM Partners’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-135,907
Closed -$4.54M – 24
2021
Q2 		$4.54M Hold
135,907
– – 0.76% 28
2021
Q1 		$2.8M Sell
135,907
-34,093
-20% -$783K 0.52% 36
2020
Q4 		$2.98M Buy
+170,000
New +$3.06M 0.35% 51

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

DSAM Partners's CLDX Position: Q3 2021 in Review

DSAM Partners sold out of Celldex Therapeutics (CLDX) in Q3 2021, closing a stake of 135,907 shares — an estimated $4.54M sold.

DSAM Partners first reported a position in CLDX in Q4 2020 and held it in 3 quarters. The position peaked at $4.54M in Q2 2021. 160 funds tracked by Wall St. Rank hold CLDX as of Q3 2021.

  • DSAM Partners reported no remaining Celldex Therapeutics position as of Q3 2021 after selling out during the quarter.
  • DSAM Partners sold 135,907 Celldex Therapeutics shares in Q3 2021, an estimated $4.54M.
  • DSAM Partners first reported a position in Celldex Therapeutics in Q4 2020 and held it in 3 quarters.
  • DSAM Partners's Celldex Therapeutics position peaked at $4.54M in Q2 2021.
  • 160 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2021.

Based on DSAM Partners's 13F filing for Q3 2021, filed 15 Nov 2021.